Skip to main content
. 2022 Jul 13;12:882940. doi: 10.3389/fonc.2022.882940

Table 1.

Strategies for resistance to BRAF inhibitors.

Situation Strategies Ref.
BRAF fusion pan-RAF inhibitors (75)
BRAF inhibitors and RAF inhibitors (76, 77)
combination of MEK inhibitors and EGFR inhibitors (25, 77)
Acquired drug resistance to vemurafenib intermittent dosing (7880)
Changes in multiple key tumorigenesis pathways and mechanisms low toxicity “broad-spectrum” treatment (81)
Resistant mutations at different gene target different drug combinations (82)